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Synopsis 
Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are both common 
causes of breathlessness and often conspire to confound accurate diagnosis and optimal 
therapy. Risk factors (such as aging, smoking and obesity) and clinical presentation (for 
instance, cough and breathlessness on exertion) can be very similar, but the treatment and 
prognostic implications are very different. In this review, we discuss the diagnostic 
challenges in individuals with exertional dyspnoea. We also highlight the prevalence, clinical 
relevance and therapeutic implications of a concurrent diagnosis of COPD and heart failure.  
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Key Points: 
 
 COPD and heart failure are both common and share many risk factors  
 Heart failure and COPD frequently co-exist and such patients have a poor prognosis 
 Determining whether breathlessness is due predominantly to lung or heart disease can 
be difficult; missed diagnoses are common  
 The combined effect of treatments for HFrEF on outcome is large and therefore the 
diagnosis should not be missed 
 COPD may deter the introduction or dose of beta-blockers, a key treatment for HFrEF 
 Treatments do not substantially alter outcomes for COPD or HFpEF 
 
Introduction 
Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are increasingly 
common and often co-exist. Together they probably cause or complicate about 10% of all 
hospital admissions. However, perhaps fewer than half of patients who have these conditions 
have appropriate investigation and diagnosis. Furthermore, the diagnosis of one condition 
may obscure the presence of the other (1, 2). HF and COPD have much in common, 
including risk factors (for instance, a lifelong history of smoking and obesity), symptoms 
(breathlessness and cough) and clinical signs (lung crackles and peripheral oedema). 
Differentiating between the two conditions is a diagnostic challenge, but their correct 
identification is essential: the correct treatment will improve the long-term outcome of many 
patients with heart failure, whereas there is little treatment that has a profound impact on 
outcome for COPD (3, 4). 
In this review, we will discuss the diagnostic challenges in distinguishing COPD from 
chronic heart failure in patients with exertional dyspnoea. We will also discuss the 
prevalence, clinical relevance and therapeutic implications associated with a concurrent 
diagnosis of COPD and heart failure. 
 
COPD and heart failure: a diagnostic challenge 
 
Clinical history and physical examination 
An 
 
 
Chest-x ray and other radiological findings 
 
Spirometry 
 
Biomarkers  
With rare exceptions (such as constrictive pericarditis), when intra-cardiac pressures rise or 
renal water and salt retention occur leading to fluid overload, the heart produces natriuretic 
peptides (NPs) as a counter-regulatory strategy designed to cause natriuresis and vasodilation.  
Increasing plasma concentrations of NPs are the single most powerful predictor of adverse 
outcome in patients with heart failure, regardless of left ventricular ejection fraction (17, 18). 
A normal plasma concentration of NPs rules out serious cardiac dysfunction (in constrictive 
pericarditis, plasma concentrations of NPs are lower than expected from the clinical picture 
but rarely normal). The diagnostic utility of NPs is currently recognised by all international 
guidelines on heart failure, including the National Institute for Health and Care Excellence 
and the European Society for Cardiology, to rule out important cardiac dysfunction in 
patients with suspected HF, acute or chronic (3). 
 
Screening studies suggest that up to 50% of patients with COPD have increased plasma 
concentrations of NPs, although no large definitive study exists (table 1)19-22. Raised plasma 
NPs in patients with COPD predict a higher mortality, whether or not they have received a 
diagnosis of HF (23, 24). For patients with COPD, increased plasma concentrations of high-
sensitivity troponin-I, suggesting ongoing myocardial damage, are also associated with high 
rates of CV events, but not with exacerbations of COPD (25). No blood biomarkers are 
currently recommended for the identification of people with COPD.  Patients with an 
elevated plasma concentration of NP should be investigated further, usually by 
echocardiography. 
 
Echocardiography 
Cardiac imaging (most commonly echocardiography) is an essential investigation for 
breathless patients who have an elevated plasma NP or in whom a cardiac contribution to 
breathlessness is suspected or needs to be excluded. It is important not to miss patients with a 
reduced left ventricular ejection fraction or severe valve disease, for which highly effective 
treatments exist. If these abnormalities are excluded, a dilated left atrium implies that the 
patient has abnormal left ventricular diastolic function and suggests the diagnosis of HFpEF. 
An echocardiogram should be considered in patients with an exacerbation of COPD, as 
around 25% of patients will have an important, potentially treatable, underlying heart 
problem (26, 27).   
 
How common are COPD and heart failure? 
“getting older” or “being unfit ”
COPD, whilst the prevalence of heart 
failure is perhaps 1-2%. Many reports suggest that a large proportion of breathlessness 
patients have both conditions (tables 226, 29-36 and 337-48). It’s worth noting that the diagnosis 
of “heart failure” includes those with either a reduced (HFrEF) or preserved (HFpEF) left 
ventricular ejection fraction on imaging, which have a similar prevalence. 
 
In surveys of COPD, heart failure is espite 
the high prevalence of ischaemic heart disease, smoking, and echocardiographic 
abnormalities in patients with COPD, COPD itself is, surprisingly, not strongly associated 
with heart failure in epidemiological studies. Perhaps once a diagnosis of COPD is made, 
clinicians do not look for other problems to explain symptoms. However, missing a diagnosis 
of 
Prevalence and prognostic relevance of COPD in people with HF
The prevalence of COPD amongst patients with HF ranges from 10-20% in large trials and 
registries where COPD was either self-reported by patients or based on the opinion (non-
standardized) of researchers (table 3). In smaller studies that used lung function tests to 
evaluate airflow obstruction objectively, up to 50% of patients with HF have abnormal 
spirometry. This wide discrepancy might suggest that the diagnosis of COPD is often missed, 
perhaps because cardiologists pay little attention to airway disease in the presence of a more 
deadly, but treatable, condition. However, it is also possible that HF has effects on the lung 
that mimic the effects of COPD leading to over-diagnosis. Interstitial lung oedema can 
compress alveoli and distal airways; cardiomegaly or pleural effusion can reduce the intra-
thoracic space and compress lung volumes; decreased respiratory muscle strength can reduce 
inspiratory and expiratory forces; frailty may impair the ability to perform spirometry 
accurately and normal values in those aged >80 years of age are not well-defined, which 
might lead to over-diagnosis by spirometry (49). Moreover, effective 
and reduce hospitalisations for respiratory infection (50, 51). 
Interpreting spirometric data in a patient with poorly controlled heart failure can be difficult.
factors (such as a 
lower use of HF medications in patients with concurrent COPD and HFrEF) is not clear (53-
55). 
 
Therapeutic concerns  
Beta-blockers improve the long-term prognosis of patients with HF due to left ventricular 
systolic dysfunction (3, 56). However, concerns about the potential for beta-blockers to cause 
bronchoconstriction and block the effect of sympathomimetic bronchodilators dissuades 
many from giving these agents in adequate doses, if at all, to patients with concomitant heart 
failure and COPD (table 3). However, the available clinical evidence suggests that these fears 
are unfounded. Small randomised trials show that any decline in FEV1 associated with beta-
blockers does not translate into worsening symptoms or quality of life in patients with HF 
and COPD (57, 58).  The use of a cardio selective beta-blocker, such as bisoprolol or 
nebivolol, might be preferred, at least theoretically, when there is concern about tolerability 
(59, 60).  
 
Perhaps surprisingly, there is accumulating evidence from observational studies and sub-
analyses from randomised trials conducted in patients with COPD which suggest that a 
higher heart rate is associated with an increase in mortality, and that beta-blockers might 
reduce exacerbations of COPD and prolong survival (61-63). Some of this apparent benefit 
might reflect inadvertent, “accidental” treatment of undiagnosed heart failure. A multicenter, 
prospective, randomized, double-blind, placebo-controlled trial is currently ongoing to test 
whether metoprolol reduces time to first exacerbation of COPD and of cardiovascular events 
in patients with moderate to severe COPD (ClinicalTrials.gov Identifier: NCT02587351) 
(64).    
 
There is no evidence that treatment for COPD improves long-term survival substantially. 
Beta-agonists can improve lung function tests in patients with COPD, but they might worsen 
cardiovascular and HF outcomes, especially for patients with HFrEF who are not protected 
by beta-blockers (65-67). Inhaled steroids may increase the risk of pneumonia (68). Oral 
steroids may increase sodium and water retention (69). Certainly, a large proportion of 
patients with COPD can tolerate de-escalation of respiratory therapies, particularly those at 
low risk of exacerbations. Attempts to identify patients in whom treatments for COPD can be 
discontinued should be encouraged (70, 71).       
 
Conclusions 
Neither COPD nor HF has a robust definition, creating uncertainty about the true prevalence 
of either condition. Missed diagnoses are common especially when one or other condition 
provides a seemingly adequate explanation for a patient’s symptoms. However, there is no 
doubt that these two conditions commonly co-exist. 
For patients with COPD, no specific treatment improves survival but they have high rates of 
cardiovascular events, and often die of the consequences. Greater focus on cardiovascular 
rather than respiratory disease in patients with COPD might improve outcomes. However, 
there is no doubt that appropriate treatment reduces the morbidity and mortality of patients 
with HFrEF, with or without co-existing COPD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
1) Peña VS, Miravitlles M, Gabriel R, et al. Geographic variations in prevalence and 
underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. 
Chest. 2000;118:981-9. 
2) van Riet EE, Hoes AW, Limburg A, Landman MA, van der Hoeven H, Rutten FH. 
Prevalence of unrecognized heart failure in older persons with shortness of breath on 
exertion. Eur J Heart Fail. 2014;16:772-7. 
3) Ponikowski P, Voors AA, Anker SD, et al.; Authors/Task Force Members.; Document 
Reviewers.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic 
heart failure: The Task Force for the diagnosis and treatment of acute and chronic 
heart failure of the European Society of Cardiology (ESC). Developed with the 
special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart 
Fail. 2016;18:891-975.  
4) Calzetta L, Rogliani P, Matera MG, Cazzola M.A Systematic Review With Meta-
Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable 
COPD. Chest. 2016;149:1181-96. 
5) Holleman DR Jr, Simel DL. Does the clinical examination predict airflow limitation? 
JAMA. 1995;273:313-9. 
6) Pellicori P, Shah P, Cuthbert J, et al. Prevalence, pattern and clinical relevance of 
ultrasound indices of congestion in outpatients with heart failure. Eur J Heart Fail. 
2019 Jan 22. doi: 10.1002/ejhf.1383. [Epub ahead of print] 
7) Sze S, Pellicori P, Kamzi S, Anton A, Clark AL. Effect of beta-adrenergic blockade 
on weight changes in patients with chronic heart failure. Int J Cardiol. 2018;264:104-
112.  
8) Sze S, Pellicori P, Kazmi S, et al. Prevalence and Prognostic Significance of 
Malnutrition Using 3 Scoring Systems Among Outpatients With Heart Failure: A 
Comparison With Body Mass Index. JACC Heart Fail. 2018;6:476-486.  
9) Clark AL, Coats AJ. Unreliability of cardiothoracic ratio as a marker of left 
ventricular impairment: comparison with radionuclide ventriculography and 
echocardiography. Postgrad Med J. 2000;76(895):289-91. 
10) Davie AP, Francis CM, Love MP, et al. Value of 
the electrocardiogram in identifying heart failure due to left ventricular systolic 
dysfunction. BMJ. 1996;312:222. 
11) Larssen MS, Steine K, Hilde JM, et al. Mechanisms of ECG signs in chronic 
obstructive pulmonary disease. Open Heart. 2017;4:e000552.  
12) Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, 
Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. 
GOLD Executive Summary. Am J Respir Crit Care Med. 2017;195:557-582.  
13) Woodruff PG, Barr RG, Bleecker E,  et al.; SPIROMICS Research Group. Clinical 
significance of symptoms in smokers with preserved pulmonary function. N Engl J 
Med 2016;374:1811–1821. 
14) Aaron SD, Tan WC, Bourbeau J, et al.; Canadian Respiratory Research Network. 
Diagnostic Instability and Reversals of Chronic Obstructive Pulmonary Disease 
Diagnosis in Individuals with Mild to Moderate Airflow Obstruction. Am J Respir 
Crit Care Med. 2017;196:306-314. 
15) Perez-Padilla R, Wehrmeister FC, Montes de Oca M, et al.; PLATINO group. 
Instability in the COPD diagnosis upon repeat testing vary with 
the definition of COPD. PLoS One. 2015;10:e0121832.  
16) Regan EA, Lynch DA, Curran-Everett D, et al.; Genetic Epidemiology of COPD 
(COPDGene) Investigators. Clinical and Radiologic Disease in Smokers With Normal 
Spirometry. JAMA Intern Med. 2015; 175:1539-49. 
17) Zhang J, Pellicori P, Pan D, Dierckx R, Clark AL, Cleland JGF. Dynamic risk 
stratification using serial measurements of plasma concentrations of natriuretic 
peptides in patients with heart failure. Int J Cardiol. 2018;269:196-200.  
18) Cleland JG, Pellicori P. Defining diastolic heart failure and identifying effective 
therapies. JAMA. 2013;309:825-6.  
19) Rutten FH, Cramer MJ, Zuithoff NP et al. Comparison of B-type natriuretic peptide 
assays for identifying heart failure in stable elderly patients with a clinical diagnosis 
of chronic obstructive pulmonary disease. Eur J Heart Fail. 2007;9:651-9.  
20) Watz H, Waschki B, Boehme C, Claussen M, Meyer T, Magnussen H. 
Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: 
a cross-sectional study. Am J Respir Crit Care Med. 2008;177:743-51.  
21) Gale CP, White JE, Hunter A, et al. Predicting mortality and hospital admission in 
patients with COPD: significance of NT pro-BNP, clinical and echocardiographic 
assessment. J Cardiovasc Med (Hagerstown). 2011;12:613-8 
22) Macchia A, Rodriguez Moncalvo JJ, et al. Unrecognised ventricular 
dysfunction in COPD. Eur Respir J. 2012;39:51-8.  
23) Pavasini R, Tavazzi G, Biscaglia S, et al. Amino terminal pro brain natriuretic 
peptide predicts all-cause mortality in patients with chronic obstructive pulmonary 
disease: Systematic review and meta-analysis. Chron Respir Dis. 2017;14:117-126.  
24) Hawkins NM, Khosla A, Virani SA, McMurray JJ, FitzGerald JM.B-type natriuretic 
peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulm 
Med. 2017;17:11.  
25) Adamson PD, Anderson JA, Brook RD, et al. Cardiac Troponin I and Cardiovascular 
Risk in Patients With Chronic Obstructive Pulmonary Disease. J Am Coll 
Cardiol. 2018;72:1126-1137.  
26) Freixa X, Portillo K, Paré C, et al; PAC-COPD Study 
Investigators.Echocardiographic abnormalities in patients with COPD at 
their first hospital admission.Eur Respir J. 2013;41:784-91. 
27) Houben-Wilke S, Spruit MA, Uszko-Lencer NHMK, et al. 
Echocardiographic abnormalities and their impact on health status 
in patients with COPD referred for pulmonary rehabilitation. 
Respirology. 2017;22:928-934.   
28) Pellicori P, Cleland JG, Zhang J et al. Cardiac Dysfunction, Congestion and Loop 
Diuretics: their Relationship to Prognosis in Heart Failure. Cardiovasc Drugs 
Ther. 2016;30:599-609. 
29) Divo M, Cote C, de Torres JP, et al.; BODE Collaborative Group. Comorbidities and 
risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir 
Crit Care Med. 2012;186:155-61.  
30) Cazzola M, Bettoncelli G, Sessa E, Cricelli C, Biscione G. Prevalence of 
comorbidities in patients with chronic obstructive pulmonary disease. 
Respiration. 2010;80:112-9.  
31) Curkendall SM, DeLuise C, Jones JK, et al.Cardiovascular disease in patients with 
chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease 
in COPD patients. Ann Epidemiol. 2006;16:63-70.  
32) Holguin F, Folch E, Redd SC, Mannino DM.Comorbidity and mortality in COPD-
related hospitalizations in the United States, 1979 to 2001. Chest. 2005;128:2005-11. 
33) McCullough PA, Hollander JE, Nowak RM, et al; BNP Multinational Study 
Investigators. Uncovering heart failure in patients with a history of pulmonary 
disease: rationale for the early use of B-type natriuretic peptide in the emergency 
department. Acad Emerg Med. 2003;10:198-204. 
34) Spece LJ, Epler EM, Donovan LM, et al. Role of Comorbidities in Treatment and 
Outcomes after Chronic Obstructive Pulmonary Disease Exacerbations. Ann Am 
Thorac Soc. 2018;15:1033-1038.  
35) Boudestein LC, Rutten FH, Cramer MJ, Lammers JW, Hoes AW.The impact of 
concurrent heart failure on prognosis in patients with chronic obstructive pulmonary 
disease. Eur J Heart Fail. 2009;11:1182-8.  
36) Kaszuba E, Odeberg H, Råstam L, Halling A.Impact of heart failure and other 
comorbidities on mortality in patients with chronic obstructive pulmonary disease: a 
register-based, prospective cohort study. BMC Fam Pract. 2018;19:178.  
37) De Blois J, Simard S, Atar D, Agewall S; Norwegian Heart Failure Registry. COPD 
predicts mortality in HF: the Norwegian Heart Failure Registry. J Card 
Fail. 2010;16:225-9.  
38) Mentz RJ, Schmidt PH, Kwasny MJ, et al.The impact of chronic obstructive 
pulmonary disease in patients hospitalized for worsening heart failure with reduced 
ejection fraction: an analysis of the EVEREST Trial. J Card Fail. 2012;18:515-23.  
39) Canepa M, Straburzynska-Migaj E, Drozdz J, et al; ESC-HFA Heart Failure Long-
Term Registry Investigators. Characteristics, treatments and 1-year prognosis of 
hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary 
disease in the European Society of Cardiology Heart Failure Long-Term Registry. Eur 
J Heart Fail. 2018;20:100-110.  
40) Canepa M, Temporelli PL, Rossi A, et al; GISSI-HF Investigators. Prevalence and 
Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with 
Chronic Heart Failure: Data from the GISSI-HF Trial. Cardiology. 2017;136:128-137.  
41) Tavazzi L, Swedberg K, Komajda M, et al; SHIFTInvestigators. Clinical profiles and 
outcomes in patients with chronic heart failure and chronic obstructive pulmonary 
disease: an efficacy and safety analysis of SHIFT study.Int J Cardiol. 2013;170:182-8. 
42) Parissis JT, Andreoli C, Kadoglou N, et al. Differences in clinical characteristics, 
management and short-term outcome between acute heart failure patients chronic 
obstructive pulmonary disease and those without this co-morbidity. Clin Res 
Cardiol. 2014;103:733-41.  
43) Mentz RJ, Fiuzat M, Wojdyla DM, et al. Clinical characteristics and outcomes of 
hospitalized heart failure patients with systolic dysfunction and chronic obstructive 
pulmonary disease: findings from OPTIMIZE-HF.Eur J Heart Fail. 2012;14:395-403.  
44) Cuthbert JJ, Kearsley JW, Kazmi S, et al.The impact of heart failure and chronic 
obstructive pulmonary disease on mortality in patients presenting with breathlessness. 
Clin Res Cardiol. 2019;108:185-193 
45) Jacob J, Tost J, Miró Ò, Herrero P, Martín-Sánchez FJ, Llorens P; ICA-SEMES 
Research Group.Impact of chronic obstructive pulmonary disease on clinical course 
after an episode of acute heart failure. EAHFE-COPD study.Int J Cardiol. 
2017;227:450-456.  
46) Iversen KK, Kjaergaard J, Akkan D, et al; ECHOS Lung Function Study Group.The 
prognostic importance of lung function in patients admitted with heart failure. Eur J 
Heart Fail. 2010;12:685-91.  
47) Plesner LL, Dalsgaard M, Schou M, et al.The prognostic significance of lung function 
in stable heart failure outpatients. Clin Cardiol. 2017;40:1145-1151.  
48) Yoshihisa A, Takiguchi M, Shimizu T, et al.Cardiovascular function and prognosis of 
patients with heart failure coexistent with chronic obstructive pulmonary disease. J 
Cardiol. 2014;64:256-64.  
49) Pellicori P, Salekin D, Pan D, Clark AL.This patient is not breathing properly: is this 
COPD, heart failure, or neither? Expert Rev Cardiovasc Ther. 2017;15:389-396.  
50) Brenner S, Güder G, Berliner D, et al. Airway obstruction in systolic heart failure--
COPD or congestion? Int J Cardiol. 2013;168:1910-6.  
51) Krahnke JS, Abraham WT, Adamson PB, et al; Champion Trial Study Group. Heart 
failure and respiratory hospitalizations are reduced in patients with heart failure and 
chronic obstructive pulmonary disease with the use of an implantable pulmonary 
artery pressure monitoring device. J Card Fail. 2015;21:240-9. 
52) Lawson CA, Mamas MA, Jones PW, et al. Association of Medication Intensity and 
Stages of Airflow Limitation With the Risk of Hospitalization or Death in Patients 
With Heart Failure and Chronic Obstructive Pulmonary Disease. JAMA Netw 
Open. 2018;1:e185489.  
53) Kapoor JR, Kapoor R, Ju C, Heidenreich PA, et al. 
Precipitating Clinical Factors, Heart Failure  
Characterization,and Outcomes in PatientsHospitalized With Heart Failure With Redu
ced, Borderline, and Preserved Ejection Fraction. JACC Heart Fail. 2016;4:464-72.  
54) Platz E, Jhund PS, Claggett BL, et al. Prevalence and prognostic importance 
of precipitating factors leading to heart failure hospitalization: recurrent 
hospitalizations and mortality. Eur J Heart Fail. 2018;20:295-303.  
55) Arrigo M, Gayat E, Parenica J, et al; GREAT Network. Precipitating factors and 90-
day outcome of acute heart failure: a report from the intercontinental GREAT 
registry. Eur J Heart Fail. 2017;19:201-208.  
56) Cleland JGF, Bunting KV, Flather MD, at al; Beta-blockers in Heart Failure 
Collaborative Group.Beta-blockers for heart failure with reduced, mid-range, and 
preserved ejection fraction: an individual patient-level analysis of double-blind 
randomized trials. Eur Heart J. 2018;39:26-35.  
57) Hawkins NM, MacDonald MR, Petrie MC, et al. Bisoprolol in patients with heart 
failure and moderate to severe chronic obstructive pulmonary disease: a randomized 
controlled trial. Eur J Heart Fail. 2009;11:684-90. 
58) Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in 
patients with chronic heart failure and chronic obstructive pulmonary disease: a 
randomized crossover trial. J Am Coll Cardiol. 2010;55:1780-7. 
59) Düngen HD, Apostolovic S, Inkrot S, et al; CIBIS-ELD investigators and Project 
Multicentre Trials in the Competence Network Heart Failure. Titration to target dose 
of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. 
Eur J Heart Fail. 2011;13:670-80. 
60) Sessa M, Mascolo A, Mortensen RN, et al. Relationship between heart failure, 
concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish 
nationwide cohort study. Eur J Heart Fail. 2018;20:548-556.  
61) Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of mortality and 
exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS 
One. 2014;9:e113048.  
62) Bhatt SP, Wells JM, Kinney GL, et al; COPDGene Investigators.β-
Blockers are associated with a reduction in COPD exacerbations. Thorax. 2016;71:8-
14.  
63) Byrd JB, Newby DE, Anderson JA, et al; SUMMIT Investigators. Blood 
pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the 
SUMMIT trial. Eur Heart J. 2018;39:3128-3134.  
64) Bhatt SP, Connett JE, Voelker H, et al.β-Blockers for the prevention of acute 
exacerbations of chronic obstructive pulmonary disease(βLOCK COPD): 
a randomised controlled study protocol. BMJ Open. 2016;6:e012292.  
65) Salpeter SR, Ormiston TM, Salpeter EE.Cardiovascular effects of beta-
agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125:2309-
21. 
66) Gershon A, Croxford R, Calzavara A, et al.Cardiovascular safety of inhaled long-
acting bronchodilators in individuals with chronic obstructive pulmonary disease. 
JAMA Intern Med. 2013;173:1175-85.  
67) Bermingham M, O'Callaghan E, Dawkins I, et al. Are beta2 
agonists responsible for increased mortality in heart failure? Eur 
J Heart Fail. 2011;13:885-91.  
68) Oba Y, Keeney E, Ghatehorde N, Dias S. Dual combination therapy versus long-
acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a 
systematic review and network meta-analysis. Cochrane Database Syst 
Rev. 2018;12:CD012620.  
 
69) Ericson-Neilsen W, Kaye AD.Steroids: pharmacology, complications, 
and practice delivery issues. Ochsner J. 2014;14:203-7. 
70) Magnussen H, Disse B, Rodriguez-Roisin R et al; WISDOM 
Investigators.Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N 
Engl J Med. 2014;371:1285-94. 
71) Chapman KR, Hurst JR, Frent SM, et al. Long-Term Triple Therapy De-escalation to 
Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease 
(SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. Am J 
Respir Crit Care Med. 2018;198:329-339.  
–
–
–
–
–
–
–
–
 T
ab
le
 2
: p
re
va
le
nc
e 
of
 h
ea
rt 
fa
ilu
re
 in
 p
at
ie
nt
s w
ith
 C
O
PD
.  
A
bb
re
vi
at
io
ns
 u
se
d:
 B
B
 –
 b
et
a-
bl
oc
ke
rs
; L
V
EF
 –
 le
ft 
ve
nt
ric
ul
ar
 e
je
ct
io
n 
fr
ac
tio
n;
 
H
Fp
EF
 –
 h
ea
rt 
fa
ilu
re
 w
ith
 p
re
se
rv
ed
 L
V
EF
; H
Fr
EF
 –
 h
ea
rt 
fa
ilu
re
 w
ith
 re
du
ce
d 
LV
EF
; C
V
 –
 c
ar
di
ov
as
cu
la
r; 
LV
SD
 –
 le
ft 
ve
nt
ric
ul
ar
 s
ys
to
lic
 
dy
sf
un
ct
io
n;
 E
R
S 
- E
ur
op
ea
n 
R
es
pi
ra
to
ry
 S
oc
ie
ty
; A
TS
 - 
A
m
er
ic
an
 T
ho
ra
ci
c 
So
ci
et
y;
 IC
D
 - 
In
te
rn
at
io
na
l C
la
ss
ifi
ca
tio
n 
of
 D
is
ea
se
s. 
 

–
–
–
–
–
–
–
–
–
